KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Common Equity (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Common Equity for 16 consecutive years, with $48.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 86.58% to $48.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.8 million, a 86.58% decrease, with the full-year FY2025 number at $48.8 million, down 86.58% from a year prior.
  • Common Equity was $48.8 million for Q4 2025 at Halozyme Therapeutics, down from $503.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $503.9 million in Q3 2025 to a low of $48.8 million in Q4 2025.
  • A 5-year average of $234.4 million and a median of $223.1 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 334.11% in 2024, then crashed 86.58% in 2025.
  • Halozyme Therapeutics' Common Equity stood at $197.0 million in 2021, then fell by 13.79% to $169.8 million in 2022, then crashed by 50.64% to $83.8 million in 2023, then surged by 334.11% to $363.8 million in 2024, then plummeted by 86.58% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Common Equity are $48.8 million (Q4 2025), $503.9 million (Q3 2025), and $332.7 million (Q2 2025).